Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 411Lymphoma 304Carcinoma, Non-Small-Cell Lung 262Melanoma 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 251Prostatic Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 242Leukemia, Myeloid, Acute 222Lung Neoplasms 215Neoplasms 209Colonic Neoplasms 209Lymphoma, Non-Hodgkin 207Lymphoma, Large B-Cell, Diffuse 204Leukemia 200Multiple Myeloma 197Lymphoma, Follicular 197Colorectal Neoplasms 190Rectal Neoplasms 188Ovarian Neoplasms 184Burkitt Lymphoma 179Brain Neoplasms 171Neoplasm Metastasis 166Lymphoma, Mantle-Cell 163Carcinoma, Renal Cell 163Glioblastoma 161Sarcoma 156Pancreatic Neoplasms 147Lymphoma, B-Cell, Marginal Zone 143Unspecified Adult Solid Tumor, Protocol Specific 138Gliosarcoma 133

Interventions

obeticholic acid 1Specimen Handling 1Erlotinib Hydrochloride 1Endoscopy, Gastrointestinal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Attenuated familial adenomatous polyposis × Clear all
NCT05223036 2026-05-14

Testing Obeticholic Acid for Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled
Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡